ACM
PTGX icon

ADAR1 Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

ADAR1 Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-132,000
Closed -$5.1M – 240
2024
Q4 		$5.1M Buy
+132,000
New +$5.75M 1.02% 23

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

ADAR1 Capital Management's PTGX Position: Q2 2026 in Review

ADAR1 Capital Management reduced its Protagonist Therapeutics (PTGX) stake by 3.3% in Q2 2026, selling an estimated $3.47M and leaving 960,863 shares worth $118M. The position accounts for 5.39% of the portfolio, ranked #2.

ADAR1 Capital Management first reported a position in PTGX in Q4 2023 and has held it in 11 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • ADAR1 Capital Management held 960,863 shares of Protagonist Therapeutics worth $118M as of Q2 2026.
  • ADAR1 Capital Management sold 33,256 Protagonist Therapeutics shares in Q2 2026, an estimated $3.47M.
  • Protagonist Therapeutics made up 5.39% of ADAR1 Capital Management's portfolio in Q2 2026, its #2 holding.
  • ADAR1 Capital Management first reported a position in Protagonist Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.